

Heart Failure and Hyperkalemia Applying Evidence-Based Medicine for Improved Patient Outcomes CME

MONDAY, SEPTEMBER 17, 2018

TIME: 6:00 PM - 8:00 PM

VENUE: GAYLORD OPRYLAND HOTEL & CONVENTION CENTER, NASHVILLE, TENNESSEE

ROOM: PRESIDENTIAL B

MODERATOR

Ileana L. Piña, MD, MPH
Professor of Medicine
Professor of Epidemiology
and Population Health
Associate Chief for
Academic Affairs
Albert Einstein College of
Medicine
Montefiore Einstein Center
for Heart and Vascular Care
Bronx, New York

FACULTY

**Katherine E. Di Palo,
PharmD**
Director
Heart Failure Hospital
Readmissions Reduction
Program
Montefiore Medical Center
Bronx, New York

Bertram Pitt, MD
Professor of Medicine
Emeritus
University of Michigan
School of Medicine
Ann Arbor, Michigan

AGENDA

6:00 PM
Introduction and pretest
Ileana L. Piña, MD, MPH

6:20 PM
*Case 1: Patient With HF,
Obesity, and T2D*
Bertram Pitt, MD

7:00 PM
*Case 2: Patient With HF,
CKD Stage 3, T2D*
Katherine E. Di Palo,
PharmD

7:30 PM
*Summary, Posttest,
and Conclusion*
Ileana L. Piña, MD, MPH

7:40 PM
Q&A With the Experts
Ileana L. Piña, MD, MPH
Bertram Pitt, MD

Katherine E. Di Palo,
PharmD

TARGET AUDIENCE

This activity is intended for cardiologists, nephrologists, and primary care physicians.

GOAL STATEMENT

The goal of this activity is to discuss the management of hyperkalemia in patients with HF, and the role of emerging therapies for lowering potassium levels.

LEARNING OBJECTIVES

Upon completion of this activity, participants will:

Have increased knowledge regarding the

- Physiologic link between HF and hyperkalemia
- Mechanism of actions of new potassium- lowering drugs

Have greater competence related to

- Prescribing new treatment options for hyperkalemia
- Applying the latest data to inform treatment options for hyperkalemia
- Managing complicated patients with HF and hyperkalemia
- Implementing strategies to overcome challenges associated with hyperkalemia management in patients with HF

ACCREDITATION STATEMENT



Physicians

The Heart Failure Society of America is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Heart Failure Society of America designates this live activity for a maximum of 2.0 **AMA PRA Category 1 Credit™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Supported by an independent educational grant from Relypsa, Inc.

This satellite symposium is not part of the scientific program as planned by the Heart Failure Society of America Program Committee

Registration for the 22nd Annual Scientific Meeting and an official name badge are required to attend this symposium.